Metastatic cancer stem cells: an opportunity for improving cancer treatment?
Diehn
Maximilian
M
Cancer Center, Stanford University School of Medicine, Palo Alto, CA 94305, USA. diehn@stanford.edu
Majeti
Ravindra
R
D000818:Animals; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics; D002277:Carcinoma / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000556:secondary; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D018819:Dipeptidyl Peptidase 4 / Q000096:biosynthesis* / Q000235:genetics; D055088:Early Detection of Cancer; D057166:High-Throughput Screening Assays; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000556:secondary; D051379:Mice; D009361:Neoplasm Invasiveness / Q000235:genetics; D014411:Neoplastic Stem Cells / Q000378:metabolism* / Q000473:pathology; D011379:Prognosis
D014408:Biomarkers, Tumor; D018819:Dipeptidyl Peptidase 4